Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
about
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disordersFosaprepitant dimeglumine for the management of chemotherapy-induced nausea and vomiting: patient selection and perspectivesManagement of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetronPatient Management with Eribulin in Metastatic Breast Cancer: A Clinical Practice GuideProphylactic Management of Radiation-Induced Nausea and VomitingPalonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapyA Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and VomitingTreatment of Breakthrough and Refractory Chemotherapy-Induced Nausea and VomitingPrevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid TumorsPatient-centered management of chemotherapy-induced nausea and vomitingChemotherapy-induced nausea and vomiting: optimizing prevention and managementSerotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different?Evolving treatment paradigms for chemotherapy-induced nausea and vomitingEffectiveness of acupuncture and related therapies for palliative care of cancer: overview of systematic reviews.The First Oral Fixed-Dose Combination of Netupitant and Palonosetron for the Treatment of Chemotherapy-Induced Nausea and VomitingDifference in the emetic control among highly emetogenic chemotherapy regimens: Implementation for appropriate use of aprepitantPharmacotherapy for adverse events reduces the length of hospital stay in patients admitted to otolaryngology ward: a single arm intervention studyDelayed Chemotherapy-Induced Nausea and Vomiting: Pathogenesis, Incidence, and Current ManagementPalonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study.Feasibility of adjuvant chemotherapy with S-1 plus carboplatin followed by single-agent maintenance therapy with S-1 for completely resected non-small-cell lung cancer: results of the Setouchi Lung Cancer Group Study 1001.Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patientsAssociation between serotonin transport polymorphisms and postdischarge nausea and vomiting in women following breast cancer surgery.Compound A Inhibits Bladder Cancer Growth Predominantly via Glucocorticoid Receptor TransrepressionOutcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis.Pharmacopuncture for cancer care: a systematic review.APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroIntegrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant.Paclitaxel and trastuzumab for breast cancer.The Impact of 5-HT3RA Use on Cost and Utilization in Patients with Chemotherapy-Induced Nausea and Vomiting: Systematic Review of the Literature.A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.Cheaper Options in the Prevention of Chemotherapy-Induced Nausea and Vomiting.Multicenter nonrandomized trial of ramosetron versus palonosetron in controlling chemotherapy-induced nausea and vomiting for colorectal cancer.Effects of combined netupitant and palonosetron (NEPA), a cancer supportive care antiemetic, on the ECG of healthy subjects: an ICH E14 thorough QT trialPredictors of antiemetic alteration in pediatric acute myeloid leukemia.Palonosetron in the management of chemotherapy-induced nausea and vomiting in patients receiving multiple-day chemotherapy.The prophylactic effects of a traditional Japanese medicine, goshajinkigan, on paclitaxel-induced peripheral neuropathy and its mechanism of actionManagement of chemotherapy-induced nausea and vomiting : focus on newer agents and new uses for older agents.Clinical practice guidelines and consensus statements in oncology--an assessment of their methodological quality.Palonosetron plus single-dose dexamethasone for the prevention of nausea and vomiting in women receiving anthracycline/cyclophosphamide-containing chemotherapy: meta-analysis of individual patient data examining the effect of age on outcome in two p
P2860
Q22299116-73B16D9C-1B7A-42D4-9EF4-5CBEB8788263Q26744323-9A63C24E-B73D-426D-804C-7A6B05A9875BQ26746211-BCD00776-1D45-4410-A2B7-51D973CB39E9Q26749476-9F22AD31-D638-4F33-8E22-DA530739083EQ26783184-6DDBD3A4-1D51-4A97-ACC6-06ECC465F3E8Q26783229-0876DFE4-8184-4B5A-A29E-613DA8C5D0F1Q26784064-86EA2BF9-BAFB-4079-8C93-12A9B2C9A515Q26784070-1E1D0CE7-57BD-4EA6-974A-80E76116ABE6Q26784083-EBAB7B41-B02A-4E7A-9237-90FFDCDB6851Q26828354-CCD45C47-1009-4C7C-8EB0-920FA10EBC5AQ26852601-E299BB06-B8B7-4CF7-B09D-B61650A7B08BQ27000620-DA043C97-BF48-478E-A4F4-4B919B9213C5Q27024463-8A6E0705-DFB2-4475-9E8C-48B998260B46Q27305930-A3E0FAFC-8901-4399-A31C-3E18506662A0Q28072596-3BC6067C-6382-4249-A55E-9486728286F6Q28236344-0C7ABC41-3CBE-4D46-8823-F8A9A679EC86Q28542923-692CB042-7FEB-40DD-93AE-399F36F52D12Q30235971-ADA56182-45EF-4FED-BE07-778C873A9717Q30672833-60FCFB6F-4083-4BCA-AE10-E6C97AB85630Q30973575-BFD9FA3C-205B-478E-98BD-2975B7A319ECQ33437409-CA779AB4-5655-4CEF-8D27-2CC934EAB828Q33556570-E4719279-D4CC-44BF-AC48-10183ECDDE63Q33621722-DC6FB332-14F4-4F55-97EA-4B7855C01A5EQ33631526-B3639BA1-8D72-42AF-91CA-262A158938BBQ33652946-48EC4C42-C831-480C-ADA5-7BD52AD8F87FQ33677761-EE1E686F-CAD7-4BA5-9783-ABE88B0835E8Q33734386-4B3EC4A2-6B58-4BC2-BD85-36E043820232Q33749075-3BC1ED35-B5CD-4A54-B629-5E6001973DB4Q33774794-DCE8D5EA-1E1F-44C6-94FA-02602857702FQ33805465-743734D7-169F-42F9-A76C-471F96D5DC6FQ33809590-45576F94-59BA-4D3B-81B0-488313B81ADFQ33866119-89F0836C-00CD-46D4-965E-428C282814BCQ33879790-CD0155DB-8F7E-4521-933A-54AD63C35B51Q34011870-DCFA910B-6B97-47FC-987E-D08A0F925FFEQ34076359-58B577D0-044A-44E4-81D1-F7C79A78AB69Q34166946-782DBEDE-2ECE-44FB-BFB6-AA1C439F11D0Q34252224-8CE81A15-FFA0-4BAD-A9ED-D1751CA6869DQ34327488-D760B5A1-B8FD-497C-8314-8B27AD0825E4Q34362184-3F26500F-0FA4-4326-B9E7-798AA5FA1B90Q34368190-5319CC26-33DB-4C1C-A7B8-6FCBE5C9933B
P2860
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@ast
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@en
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@nl
type
label
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@ast
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@en
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@nl
prefLabel
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@ast
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@en
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@nl
P2093
P2860
P356
P1476
Antiemetics: American Society of Clinical Oncology clinical practice guideline update.
@en
P2093
Ann Alexis Prestrud
Anne Marie Flaherty
Barbara Freundlich
Gary H Lyman
Gary Morrow
Kamakshi V Rao
Mark G Kris
Mark R Somerfield
Maurice Chesney
Paul J Hesketh
P2860
P304
P356
10.1200/JCO.2010.34.4614
P407
P577
2011-09-26T00:00:00Z